Possibilities of gene therapies for cancer

被引:5
作者
Lashford, LS
机构
关键词
cancer; gene therapy; vectors;
D O I
10.3109/07853899708998737
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer is an acquired disease in which it is possible to identify a variety of abnormalities at a genetic level. This holds a promise that genetic manipulation of tumour cells will lead to novel therapies. As yet these approaches are constrained by available methods for obtaining gene transfer and subsequent genetic control. However, a number of strategies are already reaching the clinic, including attempts at immunotherapy, prodrug activation and improving host defence against conventional chemotherapy. Further clinical opportunities will occur with improved vector development.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 36 条
[21]  
OGASAWARA M, 1993, CANCER RES, V53, P3561
[22]  
PAPPO I, 1995, J SURG RES, V38, P218
[23]   GENE-THERAPY FOR THE TREATMENT OF RECURRENT PEDIATRIC MALIGNANT ASTROCYTOMAS WITH IN-VIVO TUMOR TRANSDUCTION WITH THE HERPES-SIMPLEX THYMIDINE KINASE GENE GANCICLOVIR SYSTEM [J].
RAFFEL, C ;
CULVER, K ;
KOHN, D ;
NELSON, M ;
SIEGEL, S ;
GILLIS, F ;
LINK, CJ ;
VILLABLANCA, JG ;
ANDERSON, WF .
HUMAN GENE THERAPY, 1994, 5 (07) :863-890
[24]   TRANSCRIPTIONAL REGULATORY SEQUENCES OF CARCINOEMBRYONIC ANTIGEN - IDENTIFICATION AND USE WITH CYTOSINE DEAMINASE FOR TUMOR-SPECIFIC GENE-THERAPY [J].
RICHARDS, CA ;
AUSTIN, EA ;
HUBER, BE .
HUMAN GENE THERAPY, 1995, 6 (07) :881-893
[25]   ALTERED GROWTH OF HUMAN COLON CANCER CELL-LINES DISRUPTED AT ACTIVATED KI-RAS [J].
SHIRASAWA, S ;
FURUSE, M ;
YOKOYAMA, N ;
SASAZUKI, T .
SCIENCE, 1993, 260 (5104) :85-88
[26]  
SKULLING JS, 1996, GYNAECOL ONCOL, V60, P72
[27]   RETROVIRUS-MEDIATED GENE-TRANSFER TO PURIFIED HEMATOPOIETIC STEM-CELLS WITH LONG-TERM LYMPHO-MYELOPOIETIC REPOPULATING ABILITY [J].
SZILVASSY, SJ ;
FRASER, CC ;
EAVES, CJ ;
LANSDORP, PM ;
EAVES, AC ;
HUMPHRIES, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8798-8802
[28]   TYPE-C RETROVIRUS INACTIVATION BY HUMAN-COMPLEMENT IS DETERMINED BY BOTH THE VIRAL GENOME AND THE PRODUCER CELL [J].
TAKEUCHI, Y ;
COSSET, FLC ;
LACHMANN, PJ ;
OKADA, H ;
WEISS, RA ;
COLLINS, MKL .
JOURNAL OF VIROLOGY, 1994, 68 (12) :8001-8007
[29]   CURRENT STATUS OF INTERLEUKIN-2 THERAPY IN CANCER [J].
TARTOUR, E ;
MATHIOT, C ;
FRIDMAN, WH .
BIOMEDICINE & PHARMACOTHERAPY, 1992, 46 (10) :473-484
[30]  
VILE RG, 1994, CANCER RES, V54, P6228